

RICT 2013

Drug Discovery and Selection

Programme

Wednesday July 3, 2013

10:00 Registration

11:30 Reaxys Workshop: Making Drug Development Easier – Reaxys Medicinal Chemistry

14:00 [Introductive remarks](#)

Dr Maria DUCA (UNIVERSITY OF NICE SOPHIA ANTIPOLIS, Nice, France)
Dr Stéphane AZOULAY (UNIVERSITY OF NICE SOPHIA ANTIPOLIS, Nice, France)
Prof. Frédérique VIDAL (UNIVERSITY OF NICE SOPHIA ANTIPOLIS, Nice, France)
Prof. Hans Ulrich STILZ (NOVO NORDISK, Cambridge, United States)
Dr Pascal GEORGE (SCT & INDEPENDENT SCIENTIFIC EXPERT & ADVISER, Longvilliers, France)

Session 1: Paul Ehrlich Prize Lecture - Sponsored by Janssen-Cilag

Session Chairmen

Prof. André TARTAR (UNIVERSITY LILLE 2, Lille, France)
Dr Sandrine VENDEVILLE (JANSSEN INFECTIOUS DISEASES, Beerse, Belgium)

14:15 Of Ionic Channels, Venom Toxins and Other Natural Substances ... and Diseases

Prof. Michel LAZDUNSKI
(INSTITUT DE PHARMACOLOGIE MOLECULAIRE ET CELLULAIRE (IPMC), Nice, France)

Session 2: Ion Channels

Session Chairman

Prof. Claudiu SUPURAN
(UNIVERSITY OF FIRENZE, Sesto Fiorentino, Italy)

15:15 Ion Channel Drug Discovery: a Medicinal Chemistry Perspective

Dr Robert OWEN
(PFIZER NEUSENTIS, Cambridge, United Kingdom)

16:00 Discovery of Potent and Selective Inhibitors of the Cardiac Sodium/Calcium Exchanger (NCX-1)

Dr Hartmut SCHIROK
(BAYER, Wuppertal, Germany)

16:45 [Coffee Break and Exhibition](#)

**Session 3: Synergies between Medicinal Chemistry and Biotechnology
Sponsored by Pierre Fabre Research Institute**

Session Chairman

Dr Pascal GEORGE
(SCT & INDEPENDENT SCIENTIFIC EXPERT & ADVISER, Longvilliers, France)

17:45 Strategies and Challenges for the Next Generation of Therapeutic Antibodies and Derivatives

RICT 2013

Drug Discovery and Selection

Programme

Dr Alain BECK
(PIERRE FABRE, St Julien-en-Genevois, France)

18:30 **Welcome Reception**

RICT 2013

Drug Discovery and Selection

Programme

Thursday July 4, 2013

Session Session 4: Case Studies, Immunology & Inflammation

Session Chairman

Dr Gordon TANG
(ROCHE, Shanghai, China)

08:45 GLPG0974, a FFA2 Antagonist from Hit to Clinic

Dr Laurent SANIERE
(GALAPAGOS, Romainville, France)

09:30 Discovery of Highly Potent, Selective and Efficacious Cathepsin S Inhibitors

Dr Wolfgang HAAP
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

Session Session 5: Fragment-Based Drug Design

Session Chairman

Dr Jean-Paul RENAUD
(NOVALIX, Ostwald, France)

08:45 Fragment Screening and Drug Design with Fluorine NMR Spectroscopy

Dr Claudio DALVIT
(UNIVERSITY OF NEUCHÂTEL, Neuchâtel, Switzerland)

09:30 All in Good Time, Exploiting Residence Time to Improve Fragment Based Drug Discovery

Dr James MURRAY
(VERNALIS, Cambridge, United Kingdom)

10:15 [Coffee Break, Poster Session and Exhibition](#)

Session Session 6: Druggability

Session Chairman

Dr Luc VAN HIJFTE
(SCT & NOVALIX, Nijmegen, The Netherlands)

10:45 Improving Compound Quality in Medicinal Chemistry

Dr Paul LEESON
(ASTRAZENECA, Nuneaton, United Kingdom)

11:30 ADMET Modelling: Where is it Worth the Effort?

Dr Richard LAW
(EVOTEC, Abingdon, United Kingdom)

Session Session 7: ChemoGenomic

Session Chairman

Dr Paola B. ARIMONDO
(INSTITUT PASTEUR - CNRS, Paris, France)

10:45 High Confidence Target and Pathway Prediction Using a Robust Chemogenomic Platform

Dr Stephen HELLIWELL
(NOVARTIS, Basel, Switzerland)

11:30 The Discovery of Small Molecule Inhibitors of Jumonji Enzymes: Probing the Epigenome

Dr Jack BROWN
(EPINOVA DPU, II TAU, GLAXOSMITHKLINE, Stevenage, United Kingdom)

12:15 [Lunch, Poster Session and Exhibition](#)

14:00 [Career Session](#)

RICT 2013

Drug Discovery and Selection

Programme

Session Session 8: Molecular Networks

Session Chairman

Prof. Hans Ulrich STILZ
(NOVO NORDISK, Cambridge, United States)

14:15 Molecular Networks : Drug Action and Genome-Informed Medicine

Prof. Giulio SUPERTI-FURGA
(RESEARCH CENTER FOR MOLECULAR MEDICINE (CEMM), Vienna, Austria)

Session Session 9: Case Studies, Anti-Infective Agents 1

Session Chairman

Dr Yves P. AUBERSON
(NOVARTIS INSTITUTE FOR BIOMEDICAL RESEARCH, Basel, Switzerland)

15:00 Natural Products as Leads for Drug Discovery

Prof. Karl-Heinz ALTMANN
(ETH ZURICH, Zürich, Switzerland)

15:45 Drugs for Bad Bugs - Strategies to Address Infections by Multidrug-resistant Bacteria

Dr Jean-Philippe SURIVET
(ACTELION, Allschwil, Switzerland)

Session Session 10: ChemBioTools

Session Chairman

Dr Aline MOULIN
(FLAMEL TECHNOLOGIES, Vénissieux, France)

15:00 Developing New Tools for Cancer Diagnostics and Therapeutics: Fluorescent Peptide Biosensors of Cyclin-Dependent Kinases

Dr May MORRIS
(CENTRE DE RECHERCHE EN BIOCHIMIE MACROMOLÉCULAIRE (CRBM) - CNRS, Montpellier, France)

15:45 Beyond Antithrombotics: Synthetic Approaches to Unravel New Therapeutic Potentials for Glycosaminoglycans

Prof. David BONNAFFÉ
(UNIVERSITY PARIS-SUD, Orsay, France)

16:30 [Coffee Break, Poster Session and Exhibition](#)

Session Session 11: Case Studies: Anti-Infective Agents 2

Sponsored by GlaxoSmithKline

Session Chairman

Dr Alexis DENIS
(GSK, Courtaboeuf, France)

17:00 Validation of Protein Kinases as Drug Targets in the African Trypanosome

Prof. Jeremy MOTTRAM
(UNIVERSITY OF GLASGOW, Glasgow, United Kingdom)

17:45 Drug Discovery for Diseases of the Developing World

Prof. Paul WYATT
(UNIVERSITY OF DUNDEE, Dundee, United Kingdom)

Session Session 12: GPCR

Session Chairman

Dr Stephan SCHANN
(DOMAIN THERAPEUTICS, Strasbourg, France)

17:00 Structure and Fragment Based Drug Design for G Protein-Coupled Receptors

Dr Miles CONGREVE
(HEPTARES, Welwyn Garden City, United Kingdom)

RICT 2013

Drug Discovery and Selection

Programme

17:45 Allosteric Modulation of the Chemokine Receptor CXCR3

Dr Nuska TSCHAMMER

(UNIVERSITY OF ERLANGEN-NÜRNBERG, Erlangen, Germany)

20:00 Symposium Banquet

RICT 2013

Drug Discovery and Selection

Programme

Friday July 5, 2013

Session 13: Breaking News

Session Chairman

Dr Frédéric DOLLE
(CEA, SERVICE HOSPITALIER FRÉDÉRIC JOLIOT, Orsay, France)

08:30 Systemic Safety by Design: a Novel Retinoic Acid Receptor Agonist for Dermatological Indications with Specific Design Parameters for Topical Administration to Manage Safety

Dr Claire BOUIX-PETER
(GALDERMA R&D, Sophia-Antipolis, France)

09:15 SOM230: A New Therapeutic Modality for Cushing's Disease

Dr Ian LEWIS
(NOVARTIS, Basel, Switzerland)

10:00 [Coffee Break, Poster Session and Exhibition](#)

Session 14: Antibody Drug Conjugates Sponsored by Pierre Fabre Research Institute

Session Chairman

Dr Alain BECK
(PIERRE FABRE, St Julien-en-Genevois, France)

10:30 Antibody-Drug Conjugates: A Promising new Paradigm in Cancer Therapy

Dr Ravi CHARI
(IMMUNOGEN, Waltham, United States)

11:15 Targeted Cancer Chemotherapy: Developing NextGen Antibody Drug Conjugates & Key factors that Influence ADC Therapeutics

Dr Jagath Reddy JUNUTULA
(GENENTECH, South San Francisco, United States)

Session 15: European Lead Factory Sponsored by ELF Chemistry SMEs : Edlris, Mercachem, Sygnature, Syncom, Taros

Session Chairman

Prof. Joachim MITTENDORF
(BAYER PHARMA AG, Wuppertal, Germany)

12:00 The European Lead Factory - A Novel Discovery Partnership Model

Dr Jörg HUESER
(BAYER PHARMA, Wuppertal, Germany)

12:35 [Lunch, Poster Session and Exhibition](#)

RICT 2013

Drug Discovery and Selection

Programme

Session 16: Case Studies, Pain & Cancer

Session Chairman

Dr Henning STEINHAGEN
(GRÜNENTHAL, Verona, Italy)

14:05 DAAO Inhibitors as Clinical Candidates

Dr Michele HEFFERNAN
(SUNOVION PHARMACEUTICALS, Marlborough, United States)

14:50 How Animal Venoms Help to Understand Pain: Acid-Sensing Ion Channels in the Pain Pathway

Dr Eric LINGUEGLIA
(CNRS-UNIVERSITY OF NICE SOPHIA ANTIPOLIS, Valbonne, France)

15:25 Discovery and Optimization of Indoline Pyrimidone PI3Kb Inhibitors for the Treatment of PTEN-deficient Cancers

Dr Frank HALLEY
(SANOFI, Vitry-sur-Seine, France)

16:10 [Poster Prizes and Conclusive Remarks](#)

Prof. Janos SAPI
(SCT & UNIVERSITY OF REIMS-CHAMPAGNE-ARDENNE, Reims, France)